Sofinnova Partners closes £574m fund to back UK biotech and medtech startups
This article covers Sofinnova Partners, a life sciences venture capital firm, closing its latest flagship vehicle, Sofinnova Capital XI, at £574m (€650m). The fund is intended to back early-stage biotech and medtech companies in Europe and North America, increasing the pool of patient capital available for clinical development and commercialisation.
Sofinnova Partners has closed its latest flagship vehicle, Sofinnova Capital XI, at £574m (€650m), significantly above its initial target. The Paris-, London- and Milan-based life sciences investor says the new fund will back early-stage biotech and medtech companies across Europe and North America, adding to a period in which the firm has raised roughly £1.3bn (€1.5bn) across its platform in the past year — a notable vote of confidence for a sector that still struggles for seed and series A capital.
Why it matters
Sofinnova Capital XI’s size and speed of close matter for entrepreneurs and for the wider European life sciences scene. Early-stage biotech and medtech companies often face long development timelines and capital intensity; a large, dedicated early-stage fund increases the pool of patient capital available for clinical development and commercialisation.
The fund’s backers include sovereign wealth funds, major pharmaceutical companies and other corporates, insurance companies, foundations and family offices from Europe, North America, Asia and the Middle East. Sofinnova says a majority of limited partners are returning investors and a meaningful portion are new top-tier institutions, which the firm frames as a validation of its long-term, science-driven investment discipline.
Inside the fund
Sofinnova Capital XI will focus on both biopharmaceuticals and medical technologies and is already deploying capital into a small number of portfolio companies. The firm says the fund will participate in initial rounds as well as follow-on financing, underlining a strategy to back companies through early value inflection points.
The close brings Sofinnova’s total platform capital to about £1.3bn (€1.5bn) over the past year, reinforcing its position as one of Europe’s larger life sciences venture firms.
Who’s behind the fund
Sofinnova Partners cites an experienced investment team that will draw on the firm’s multi-strategy platform. Named partners involved with Capital XI include Maina Bhaman, Anta Gkelou, Karl Naegler, Antoine Papiernik, Henrijette Richter and Graziano Seghezzi. The firm operates from Paris, London and Milan and has a history of supporting life sciences companies from seed through later stages.
Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners, said:
This fundraising marks a pivotal moment for Sofinnova. It gives us the firepower to double down on early-stage opportunities and reinforces our uniquely collaborative, science-driven investment approach. We’re excited to continue backing visionary entrepreneurs and advancing the next wave of breakthroughs in science and medicine to bring them to patients worldwide.
Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners, said:
Achieving this milestone in today’s volatile fundraising environment speaks to the strength of our model and the confidence our investors continue to place in us.
Where the money will go
Sofinnova positions Capital XI to back pioneering biopharma and medtech teams addressing unmet clinical needs. That typically means assets ranging from preclinical therapeutics and platform technologies to early-stage devices needing capital for clinical trials and regulatory milestones. Sofinnova’s platform approach suggests the fund will also leverage technical and commercial support alongside capital — a model common among larger European life sciences VCs.
How it fits the market
Europe has seen sporadic waves of life sciences fundraising, but many investors point to a relative shortage of staged, follow-on capital at the earliest venture rounds compared with the United States. A sizeable raise like Capital XI not only supplies direct financing but can influence syndication dynamics by anchoring rounds, which may help smaller funds and angel networks mobilise around promising spinouts from universities and research institutes.
Founder perspective
For founders, a firm with Sofinnova’s footprint — multiple offices, a track record across therapeutics and devices, and a wide LP base including corporates — can offer access to industry partners and potential exit pathways. Sofinnova’s intention to support both initial and follow-on rounds reduces the financing risk for companies that clear scientific and regulatory milestones.
The bigger picture
Sofinnova’s close arrives at a time when life sciences venture activity in Europe seeks durability and scale. Large early-stage funds can accelerate the development pipeline and help keep promising companies domiciled in Europe rather than moving to the US for growth capital. At the same time, the fund’s global LP mix highlights the ongoing international appetite for European science when backed by experienced fund managers.
The Sofinnova close is a practical indicator that committed pools of capital remain available for high-risk, long-horizon bioscience investments — a useful signal for founders, university tech transfer offices and smaller investors trying to piece together multi-round financing plans in the UK and across Europe.
Click here for a full list of 7,589+ startup investors in the UK